A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

NCT05896163 on ClinicalTrials.gov Phase 1/2 Pfizer (industry) Started 2023-08-30 Terminated

Riskier than 88% of active trials

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 29% of the time (655 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

How it ended

Terminated on 2026-04-09, after 2023-08-30 start.

Reason given by the sponsor: “business”

The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.

Termination over time, as the model saw it at the start

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-04-09. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

What moved the score

Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerlymphomarefractorytherapypatients
Phrases that lowered it: participantssingle doseparticipanthealthyfixed
Sponsor's past termination rate: 16.1% (raises risk) · Sponsor's track record
Accepts healthy volunteers: No (raises risk) · Who can join
Phase: 1/2 (raises risk) · Design
Sponsor's past trials: 2183 (raises risk) · Sponsor's track record
Disease area, cancer: Yes (raises risk) · Disease area
Drug's FAERS reports with a death: 14.2% (lowers risk) · Drug's FDA history
Trials the sponsor started in the prior 2 years: 183 (lowers risk) · Sponsor's track record
Sponsor type: industry (lowers risk) · Sponsor's track record
Minimum age: 18 (raises risk) · Who can join
Primary purpose: treatment (raises risk) · Design
Design: sequential (raises risk) · Design
Blinding: none (raises risk) · Design
Collaborators: 1 (raises risk) · Design
Has a data monitoring committee: No (lowers risk) · Design
Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

The trial

Design

Phase: 1/2 (typical: 2)
Number of arms: 2
Allocation: randomized
Design: sequential (typical: parallel)
Primary purpose: treatment
Blinding: none
Has a data monitoring committee: No (typical: 56% yes)
Responsible party: sponsor
Collaborators: 1 (typical: 0)
Keywords listed: 10 (typical: 1)

Who can join

Minimum age: 18
Maximum age: not given (typical: 71)
Sex: all
Accepts healthy volunteers: No (typical: 9% yes)

Sponsor's track record

Sponsor type: industry (typical: academic or other)
Sponsor's past trials: 2183 (typical: 32)
Sponsor's past termination rate: 16.1% (typical: 9.9%)
Trials the sponsor started in the prior 2 years: 183 (typical: 19)

Drug's FDA history

Drugs with FDA adverse-event history: 3 (typical: 1)
Drug has FAERS history: Yes (typical: 64% yes)
Drug's FAERS reports before start: 11816 (typical: 2148)
Drug's FAERS reports in the prior 12 months: 2410 (typical: 412.5)
Drug's FAERS reports marked serious: 90.5% (typical: 85.6%)
Drug's FAERS reports with a death: 14.2% (typical: 15.9%)

Disease area and drugs

Disease areas: cancer, immunology, hematology
Drugs matched to FDA substances: glofitamab, maplirpacept, obinutuzumab

Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.

Similar finished trials

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma NCT05626322 · started 2023 · scored riskier than 80% of active trials terminated
A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT04182204 · started 2020 · scored riskier than 14% of active trials completed
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers NCT06254495 · started 2024 · scored riskier than 36% of active trials terminated
AZD1152 in Diffuse Large B-cell Lymphoma NCT01354392 · started 2011 · scored riskier than 74% of active trials completed
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) NCT01238692 · started 2010 · scored riskier than 97% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.